Economic Outcomes of Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle Invasive Bladder Cancer: A 5-Year, Medicare-Based Model

BACKGROUND: Bladder cancer is the most expensive to treat on a per-patient basis. Blue light cystoscopy with hexaminolevulinate (BLC) has demonstrated improved diagnostic accuracy compared white (WLC) in non-muscle invasive bladder (NMIBC). With higher upfront costs, questions remain about long-term BLC cost outcomes. OBJECTIVE: This study seeks investigate 5-year comparison of and WLC from Medicare payer perspective. METHODS: A representative NMIBC management model was constructed reimbursement values were overlaid. The primary outcome mean year-over-year cumulative discounted present value at 3% annual percentage rate. secondary rate clinical events. RESULTS: Patients cohort experienced fewer recurrences. On basis, more per patient years 1, 2, 3 than WLC, however, 4 5, economically favorable. Year 5 savings $1,172 patient. Overall, 31.6% all patients group generated year 1 50.9% end 5. CONCLUSIONS: Despite initial cost, slight economic advantage realized after surveillance 3. Additionally, greater proportion who received achieved As novel technology emerges, models can help health care systems predict associated costs quality improvements.